These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2473610)

  • 1. Clinical benefits of iloprost, a stable prostacyclin (PGI2) analog, in severe peripheral arterial disease (PAD).
    Oberender H; Krais T; Schäfer M; Belcher G
    Adv Prostaglandin Thromboxane Leukot Res; 1989; 19():311-6. PubMed ID: 2473610
    [No Abstract]   [Full Text] [Related]  

  • 2. [Iloprost, a stable prostacyclin derivative, in stage 4 arterial occlusive disease. A placebo-controlled multicenter study].
    Diehm C; Abri O; Baitsch G; Bechara G; Beck K; Breddin HK; Brock FE; Clevert HD; Corovic D; Marshall M
    Dtsch Med Wochenschr; 1989 May; 114(20):783-8. PubMed ID: 2470569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential therapeutic mechanisms of stable prostacyclin (PGI2)-mimetics in severe peripheral vascular disease.
    Müller B; Krais T; Stürzebecher S; Witt W; Schillinger E; Baldus B
    Biomed Biochim Acta; 1988; 47(10-11):S40-4. PubMed ID: 2470358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does prostacyclin analogue Iloprost change blood rheology? Results from a double blind trial with intravenous application in diabetics.
    Ernst E; Marshall M; Matrai A
    Vasa; 1988; 17(2):89-91. PubMed ID: 2457284
    [No Abstract]   [Full Text] [Related]  

  • 5. Prostacyclin in peripheral arterial occlusive disease (PAOD): clinical and hemodynamic findings in patients with PAOD stage III and IV.
    Valentin A; Karnik R; Sehnal E; Slany J
    Prog Clin Biol Res; 1987; 242():457-62. PubMed ID: 3313420
    [No Abstract]   [Full Text] [Related]  

  • 6. Platelet responses observed during and after infusions of the prostacyclin analog ZK 36 374.
    Yardumian DA; Mackie IJ; Bull H; Machin SJ
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():359-62. PubMed ID: 2408446
    [No Abstract]   [Full Text] [Related]  

  • 7. Iloprost in peripheral vascular disease--platelet function and clinical outcome.
    Fitscha P; Tiso B; Sinzinger H
    Prog Clin Biol Res; 1987; 242():463-8. PubMed ID: 2444993
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of stable prostacyclin analogue ZK 36 374 to treat severe lower limb ischaemia.
    Chiesa R; Vicari A; Mari G; Galimberti M; Di Carlo V; Pozza G
    Lancet; 1985 Jul; 2(8446):95-6. PubMed ID: 2409417
    [No Abstract]   [Full Text] [Related]  

  • 9. A randomized, double-blind, crossover comparison of iloprost with dextran in patients with peripheral arterial occlusive disease.
    Ylitalo P; Kaukinen S; Reinikainen P; Salenius JP; Vapaatalo H
    Int J Clin Pharmacol Ther Toxicol; 1990 May; 28(5):197-204. PubMed ID: 1694831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study of the effects of taprostene (CG 4203) in patients with advanced peripheral arterial disease.
    Darius H; Kopp H; Mulfinger A; Spielberger M; Todt M; Schuster CJ; Meyer J
    Prog Clin Biol Res; 1989; 301():417-21. PubMed ID: 2508112
    [No Abstract]   [Full Text] [Related]  

  • 11. Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease. A placebo-controlled dose-response study.
    Darius H; Hossmann V; Schrör K
    Klin Wochenschr; 1986 Jun; 64(12):545-51. PubMed ID: 2426514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prostaglandins including prostacyclin in the treatment of peripheral arterial occlusive disorders].
    Alexander K
    Internist (Berl); 1989 Jul; 30(7):429-39. PubMed ID: 2670810
    [No Abstract]   [Full Text] [Related]  

  • 13. [Design and method of clinical trials of drugs used in the therapy of stable peripheral arterial occlusive disease].
    Wink K
    Arzneimittelforschung; 2006; 56(1):52-7. PubMed ID: 16478006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Our experience in using a synthetic prostacyclin analog in the treatment of critical ischemia of the extremities].
    Centorrino T; Versaci A; Ciccolo A; Terranova ML; Panté S; Barbera A; Cuzzocrea D
    G Chir; 1998 Oct; 19(10):399-403. PubMed ID: 9835185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In diabetes and peripheral arterial occlusive disease: long-term treatment with clopidogrel].
    Baumgartner I
    Praxis (Bern 1994); 2005 May; 94(19):770-1. PubMed ID: 15940908
    [No Abstract]   [Full Text] [Related]  

  • 16. A randomized, placebo controlled trial of prostacyclin (PGI2) in peripheral arterial disease.
    Hossman V; Heinen A; Auel H; FitzGerald GA
    Thromb Res; 1981 May; 22(4):481-90. PubMed ID: 7027528
    [No Abstract]   [Full Text] [Related]  

  • 17. Epoprostenol (prostacyclin) and severe arterial disease. A double-blind trial.
    Belch JJ; McKay A; McArdle B; Leiberman P; Pollock JG; Lowe GD; Forbes CD; Prentice CR
    Lancet; 1983 Feb; 1(8320):315-7. PubMed ID: 6130330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iloprost, a stable analogue of PGI2: clinical results and pathophysiological considerations.
    Stock G; Müller B; Krais T; Schillinger E
    Adv Prostaglandin Thromboxane Leukot Res; 1991; 21B():583-9. PubMed ID: 1705081
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of iloprost, a stable prostacyclin analog, on exercise capacity and platelet aggregation in stable angina pectoris.
    Bugiardini R; Galvani M; Ferrini D; Gridelli C; Mari L; Puddu P; Lenzi S
    Am J Cardiol; 1986 Sep; 58(6):453-9. PubMed ID: 2428231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possibilities for clinical use of prostacyclin in vascular disease.
    Poredos P
    Pflugers Arch; 2000; 440(5 Suppl):R137-8. PubMed ID: 11005643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.